$GENB News
Last published 1w ago
- 1w agoGENBBMYNTHIAZN2027 Could Finally Be the Year Cancer Is on the Ropes!GlobeNewswireDENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
- 2w agoGENBGenerate Biomedicines to Participate in November Investor ConferencesGlobeNewswireSOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced that members of its management team will participate in presentations at the following
- 4w agoHYFTGENBMRNAABSI+1AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestGlobeNewswireNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
- 4w agoZEALGENBZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewswirePress release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine
- 4w agoGENBZEALGenerate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewswireCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will
- 2mo agoGENBGenerate Biomedicines Inc. to Participate in September Investor ConferencesGlobeNewswireSOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced that members of its management team will participate in presentations at the
- 3mo agoGENBGenerate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireSOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a
- 4mo agoGENBAdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, MassachusettsPR NewswireIQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation...
- 5mo agoGENBGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare ConferencePR NewswireGenerate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on...
- 6mo agoGENBGenerate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business UpdatePR NewswireGenerate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted...
- 8mo agoGENBGenerate Biomedicines, Inc. Announces Pricing of Initial Public OfferingPR NewswireGenerate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology...